安达芬联合拉米呋啶治疗慢性乙型肝炎临床研究

Clinical Study of Chronic Hepatitis B Using Anterferon in Combination with Lamivudine

目的:探讨安达芬联合拉米呋啶治疗慢性乙型肝炎的近期疗效及不良反应。方法:选择116例慢性乙型肝炎患者,随机分成联合组(A组)40例,给予安达芬及拉米呋啶治疗。安达芬组(B组)38例,单用安达芬治疗;拉米呋啶组(C组)38例,单用拉米呋啶治疗。治疗结束时,观察3组患者肝功能、乙型肝炎病毒血清学标志(HBVM)的变化。结果:3组患者血清谷丙转氨酶(ALT)均较治疗前显著下降,但A组明显高于B、C2组,差异有显著性(P<0.05);HBeAg阴转率分别为57.5%、42.1%和39.55,HBV-DNA阴转率分别为67.5%、47.4%和44.7%,A组的疗效明显优于B、C2组(P<0.05),未见明显不良反应。结论:安达芬联合拉米呋啶具有改善肝功能和抑制乙肝病毒复制等功效,两者联合应用可作为治疗慢性乙型肝炎的一种治疗方案,值得在临床推广。

Objective ： To search out the short-term efficacy and side effects of chronic hepatitis B using Anterferon in combination with Lamivudine .Methods ： 116 patients were randomly divided into three groups. 40 patients as group A was given Anterferon and Lamivudine,38 patients as group B was given single Anterferon ,38 Patients as group C was given single Lamivudine.Afier completion of therapy, the ehangment of liver function and HBVM were observed. Results ：ALT was decreased in this three groups. But group A was obviously higher than group B and group C （P 〈0.05）. The negative rate of HbeA was 57.5% and 42.1% and 39.5%. The negative rate of HBV-DNA was 67.5% and 47.4% and 44.7%. Group A was higher than that of group B and group C （P 〈0.05）.Side effects had not been found. Conclusions ： Recombinant Anterferon in combination with Lamivudine can improve liver function and inhibit HBV. It is worth spreading as a clinical method.